Literature DB >> 23831166

Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population.

Susan Colilla1, Ann Crow, William Petkun, Daniel E Singer, Teresa Simon, Xianchen Liu.   

Abstract

Estimates and projections of diagnosed incidence and prevalence of atrial fibrillation (AF) in the United States have been highly inconsistent across published studies. Although it is generally acknowledged that AF incidence and prevalence are increasing due to growing numbers of older people in the U.S. population, estimates of the rate of expected growth have varied widely. Reasons for these variations include differences in study design, covered time period, birth cohort, and temporal effects, as well as improvements in AF diagnosis due to increased use of diagnostic tools and health care awareness. The objective of this study was to estimate and project the incidence and prevalence of diagnosed AF in the United States out to 2030. A large health insurance claims database for the years 2001 to 2008, representing a geographically diverse 5% of the U.S. population, was used in this study. The trend and growth rate in AF incidence and prevalence was projected by a dynamic age-period cohort simulation progression model that included all diagnosed AF cases in future prevalence projections regardless of follow-up treatment, as well as those cases expected to be chronic in nature. Results from the model showed that AF incidence will double, from 1.2 million cases in 2010 to 2.6 million cases in 2030. Given this increase in incidence, AF prevalence is projected to increase from 5.2 million in 2010 to 12.1 million cases in 2030. The effect of uncertainty in model parameters was explored in deterministic and probabilistic sensitivity analyses. Variability in future trends in AF incidence and recurrence rates has the greatest impact on the projected estimates of chronic AF prevalence. It can be concluded that both incidence and prevalence of AF are likely to rise from 2010 to 2030, but there exists a wide range of uncertainty around the magnitude of future trends.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23831166     DOI: 10.1016/j.amjcard.2013.05.063

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  308 in total

Review 1.  Management of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting: Review of the Literature.

Authors:  Ali J Khiabani; Taylan Adademir; Richard B Schuessler; Spencer J Melby; Marc R Moon; Ralph J Damiano
Journal:  Innovations (Phila)       Date:  2018 Nov/Dec

2.  Percutaneous left atrial appendage closure for stroke prevention in India: The beginning of a new era.

Authors:  Adel Aminian; Georges Khalil; Apostolos Tzikas
Journal:  Indian Heart J       Date:  2015-10-21

Review 3.  An overview of left atrial appendage occlusion devices.

Authors:  Kyle J Feldmann; Arash Arshi; Steven J Yakubov
Journal:  Curr Cardiol Rep       Date:  2015       Impact factor: 2.931

4.  Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves.

Authors:  Ajay Yadlapati; Christopher Groh; S Chris Malaisrie; Mark Gajjar; Jane Kruse; Sheridan Meyers; Rod Passman
Journal:  Clin Res Cardiol       Date:  2015-09-18       Impact factor: 5.460

5.  Associations of obesity and body fat distribution with incident atrial fibrillation in the biracial health aging and body composition cohort of older adults.

Authors:  Konstantinos N Aronis; Na Wang; Caroline L Phillips; Emelia J Benjamin; Gregory M Marcus; Anne B Newman; Nicolas Rodondi; Suzanne Satterfield; Tamara B Harris; Jared W Magnani
Journal:  Am Heart J       Date:  2015-06-14       Impact factor: 4.749

6.  Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Authors:  Aditi Shendre; Gaurav M Parmar; Chrisly Dillon; Timothy Mark Beasley; Nita A Limdi
Journal:  Pharmacotherapy       Date:  2018-02-27       Impact factor: 4.705

Review 7.  Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.

Authors:  Claudia L Zeballos-Palacios; Ian G Hargraves; Peter A Noseworthy; Megan E Branda; Marleen Kunneman; Bruce Burnett; Michael R Gionfriddo; Christopher J McLeod; Haeshik Gorr; Juan Pablo Brito; Victor M Montori
Journal:  Mayo Clin Proc       Date:  2019-01-11       Impact factor: 7.616

8.  Safety and feasibility of combined atrial fibrillation ablation and left atrial appendage occlusion after left atrial appendage electrical isolation.

Authors:  Kenneth Kita; Steven Carlson; Mary Huntsinger; Han Tun; Jina Sohn; Rahul N Doshi
Journal:  J Interv Card Electrophysiol       Date:  2019-08-03       Impact factor: 1.900

9.  Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation.

Authors:  Nancy Luo; Haolin Xu; Hani Jneid; Gregg C Fonarow; Renato D Lopes; Jonathan P Piccini; Anne B Curtis; Andrea M Russo; William R Lewis; Roland A Matsouaka; Christopher B Granger; Robert J Mentz; Sana M Al-Khatib
Journal:  Circ Heart Fail       Date:  2018-10       Impact factor: 8.790

Review 10.  Sex Differences in Atrial Fibrillation-Update on Risk Assessment, Treatment, and Long-Term Risk.

Authors:  Charlotte J Bai; Nidhi Madan; Shaza Alshahrani; Neelum T Aggarwal; Annabelle Santos Volgman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.